Parvoduk

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

živi atenuirani parvovirus duškog patka

Available from:

Merial

ATC code:

QI01BD03

INN (International Name):

live attenuated Muscovy duck parvovirus

Therapeutic group:

patke

Therapeutic area:

Imunomodulatori za Aves, parvovirus patke, živa virusna cjepiva

Therapeutic indications:

Aktivna imunizacija patke kako bi se spriječila smrtnost1 i smanjiti gubitak težine i lezije parvovirozne patke i Derzsyove bolesti. 1 U odsutnosti majčinskog protutijela.

Product summary:

Revision: 2

Authorization status:

povučen

Authorization date:

2014-04-11

Patient Information leaflet

                                Lijek koji više nije odobren
17
B. UPUTA O VMP
Lijek koji više nije odobren
18
UPUTA O VMP-U:
Parvoduk koncentrat i otapalo za injekcijsku suspenziju za mošusne
patke.
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
MERIAL
29, avenue Tony Garnier
69007 LYON
Francuska
Proizvođač odgovoran za puštanje serije u promet:
MERIAL
Laboratory of Lyon Porte des Alpes
Rue de l’Aviation,
69800 Saint-Priest
FRANCE
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Parvoduk koncentrat i otapalo za injekcijsku suspenziju za mošusne
patke.
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Svaka pripremljena doza od 0,2 ml sadrži:
Djelatna tvar:
Živi atenuirani parvovirus mošusne patke soj GM 199
....................................... 2,6 - 4,8 log
10
CCID
50
*
* Infektivna doza 50% kultura stanica.
Koncentrat i otapalo za suspenziju za injekciju.
Koncentrat je opalescentan i homogen.
Otapalo je bistro i bezbojno.
4.
INDIKACIJA(E)
Aktivna imunizacija mošusnih pataka radi smanjenja gubitka tjelesne
težine i lezija nastalih od
parvovirusa mošusne patke i Derzsy bolesti, u nedostatku majčinskih
protutijela, kako bi se spriječilo
uginuće.
Početak imunosti: 11 dana nakon prve injekcije.
Trajanje imunosti: 26 dana nakon prve injekcije.
Potvrđeno trajanje imunosti štiti ptice u razdoblju kada su
najosjetljivije na parvovirus mošusne patke
i Derszy bolest.
Lijek koji više nije odobren
19
5.
KONTRAINDIKACIJE
Ne primjenjivati pticama kad nesu.
6.
NUSPOJAVE
Nema.
Ako se zamijeti bilo koja ozbiljna nuspojava, čak i one koje nisu
navedene u ovoj uputi o VMP-u, ili
se posumnja u učinkovitost VMP-a, treba obavijestiti veterinara.
7.
CILJNE VRSTE ŽIVOTINJA
Mošusne patke.
8.
DOZIRANJE ZA SVAKU CILJNU VRSTU ŽIVOTINJA, NAČIN I PUT(EVI)
PRIMJENE
Potkožna primjena.
Primjena jedne doze od 0,2 ml potkožno, sukladno sljedećoj shemi
cijepljenja:
-
Prvo 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Lijek koji više nije odobren
1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
Lijek koji više nije odobren
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Parvoduk koncentrat i otapalo za injekcijsku suspenziju za mošusne
patke.
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka pripremljena doza od 0,2 ml sadrži:
DJELATNA TVAR:
Živi atenuirani parvovirus mošusne patke, parvovirus soj GM 199
..................... 2,6 - 4,8 log
10
CCID
50
*
* Infektivna doza 50% kultura stanica
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Koncentrat i otapalo za suspenziju za injekciju.
Koncentrat je opalescentan i homogen.
Otapalo je bistro i bezbojno.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Mošusne patke.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Aktivna imunizacija mošusnih pataka radi smanjenja gubitka tjelesne
težine i lezija nastalih od
parvovirusa mošusne patke i Derzsy bolesti, u nedostatku majčinskih
protutijela, kako bi se spriječilo
uginuće.
Početak imunosti: 11 dana nakon prve injekcije.
Trajanje imunosti: 26 dana nakon prve injekcije.
Potvrđeno trajanje imunosti štiti ptice u razdoblju kada su
najosjetljivije na parvovirus mošusne patke
i Derszy bolest.
4.3
KONTRAINDIKACIJE
Ne primjenjivati pticama kad nesu.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Cijepiti samo zdrave životinje.
4.5
POSEBNE MJERE OPREZA PRILIKOM PRIMJENE
Posebne mjere opreza prilikom primjene na životinjama
Cijelo jato treba biti procijepljeno kako bi se smanjio rizik
cirkulacije vakcinalnog i rekombinantnog
soja virusa.
Lijek koji više nije odobren
3
Posebne
mjere
opreza koje
mora
poduzeti
osoba
koja
primjenjuje
veterinarsko-medicinski
proizvod
na životinjama
Nije primjenjivo.
4.6
NUSPOJAVE (UČESTALOST I OZBILJNOST)
Nema.
4.7
PRIMJENA TIJEKOM GRAVIDITETA, LAKTACIJE ILI NESENJA
Ne primjenjivati pticama kad nesu (vidi odjeljak 4.3).
4.8
INTERAKCIJE S DRUGIM MEDICINSKIM PROIZVODIMA I DRUGI OBLICI
INTERAKCIJA
Ne postoje dostupni podaci o neškodljivosti i djelotvornosti ovog
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-04-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-04-2019
Public Assessment Report Public Assessment Report Bulgarian 15-04-2019
Patient Information leaflet Patient Information leaflet Spanish 15-04-2019
Public Assessment Report Public Assessment Report Spanish 15-04-2019
Patient Information leaflet Patient Information leaflet Czech 15-04-2019
Public Assessment Report Public Assessment Report Czech 15-04-2019
Patient Information leaflet Patient Information leaflet Danish 15-04-2019
Public Assessment Report Public Assessment Report Danish 15-04-2019
Patient Information leaflet Patient Information leaflet German 15-04-2019
Public Assessment Report Public Assessment Report German 15-04-2019
Patient Information leaflet Patient Information leaflet Estonian 15-04-2019
Public Assessment Report Public Assessment Report Estonian 15-04-2019
Patient Information leaflet Patient Information leaflet Greek 15-04-2019
Public Assessment Report Public Assessment Report Greek 15-04-2019
Patient Information leaflet Patient Information leaflet English 15-04-2019
Public Assessment Report Public Assessment Report English 15-04-2019
Patient Information leaflet Patient Information leaflet French 15-04-2019
Public Assessment Report Public Assessment Report French 15-04-2019
Patient Information leaflet Patient Information leaflet Italian 15-04-2019
Public Assessment Report Public Assessment Report Italian 15-04-2019
Patient Information leaflet Patient Information leaflet Latvian 15-04-2019
Public Assessment Report Public Assessment Report Latvian 15-04-2019
Patient Information leaflet Patient Information leaflet Lithuanian 15-04-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-04-2019
Public Assessment Report Public Assessment Report Lithuanian 15-04-2019
Patient Information leaflet Patient Information leaflet Hungarian 15-04-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 15-04-2019
Public Assessment Report Public Assessment Report Hungarian 15-04-2019
Patient Information leaflet Patient Information leaflet Maltese 15-04-2019
Public Assessment Report Public Assessment Report Maltese 15-04-2019
Patient Information leaflet Patient Information leaflet Dutch 15-04-2019
Public Assessment Report Public Assessment Report Dutch 15-04-2019
Patient Information leaflet Patient Information leaflet Polish 15-04-2019
Public Assessment Report Public Assessment Report Polish 15-04-2019
Patient Information leaflet Patient Information leaflet Portuguese 15-04-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 15-04-2019
Public Assessment Report Public Assessment Report Portuguese 15-04-2019
Patient Information leaflet Patient Information leaflet Romanian 15-04-2019
Public Assessment Report Public Assessment Report Romanian 15-04-2019
Patient Information leaflet Patient Information leaflet Slovak 15-04-2019
Public Assessment Report Public Assessment Report Slovak 15-04-2019
Patient Information leaflet Patient Information leaflet Slovenian 15-04-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 15-04-2019
Public Assessment Report Public Assessment Report Slovenian 15-04-2019
Patient Information leaflet Patient Information leaflet Finnish 15-04-2019
Public Assessment Report Public Assessment Report Finnish 15-04-2019
Patient Information leaflet Patient Information leaflet Swedish 15-04-2019
Public Assessment Report Public Assessment Report Swedish 15-04-2019
Patient Information leaflet Patient Information leaflet Norwegian 15-04-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 15-04-2019
Patient Information leaflet Patient Information leaflet Icelandic 15-04-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 15-04-2019

View documents history